AEON Biopharma, Inc. to Post Q1 2024 Earnings of ($0.31) Per Share, HC Wainwright Forecasts (NASDAQ:AEON)

AEON Biopharma, Inc. (NASDAQ:AEON) – Investment analysts at HC Wainwright upped their Q1 2024 EPS estimates for AEON Biopharma in a research report issued to clients and investors on Wednesday, April 17th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.31) per share for the quarter, up from their previous forecast of ($0.39). HC Wainwright currently has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q2 2024 earnings at ($0.31) EPS, Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.18) EPS and FY2025 earnings at ($1.16) EPS.

AEON Biopharma Price Performance

NASDAQ:AEON opened at $4.66 on Friday. The firm has a 50 day simple moving average of $10.55 and a 200-day simple moving average of $7.77. AEON Biopharma has a 1-year low of $3.37 and a 1-year high of $17.17.

AEON Biopharma (NASDAQ:AEON) last announced its quarterly earnings results on Friday, March 29th. The company reported ($0.71) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On AEON Biopharma

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of AEON Biopharma by 8.3% in the fourth quarter. Vanguard Group Inc. now owns 209,785 shares of the company’s stock valued at $1,510,000 after buying an additional 16,091 shares during the last quarter. Northern Trust Corp raised its position in shares of AEON Biopharma by 53.4% in the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock valued at $359,000 after buying an additional 17,341 shares during the last quarter. Formidable Asset Management LLC acquired a new position in shares of AEON Biopharma in the third quarter valued at approximately $360,000. Finally, Atalaya Capital Management LP acquired a new position in shares of AEON Biopharma in the third quarter valued at approximately $19,827,000. Institutional investors and hedge funds own 22.78% of the company’s stock.

About AEON Biopharma

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.